InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors
April 03, 2019 08:00 ET
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
February 27, 2019 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
February 20, 2019 07:30 ET
|
ARCA biopharma, Inc.
FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies
February 07, 2019 08:05 ET
|
InCarda Therapeutics, Inc.
U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
December 20, 2018 16:01 ET
|
ARCA biopharma, Inc.
Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...
GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
November 12, 2018 08:30 ET
|
ARCA biopharma, Inc.
AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring with implanted devices...
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
November 08, 2018 08:05 ET
|
InCarda Therapeutics, Inc.
Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial...
Double-Digit Gain in Market for Atrial Fibrillation Interventions
November 06, 2018 11:00 ET
|
BCC Research
WELLESLEY, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Catheter ablation is evolving as the first-line treatment for individuals affected with atrial fibrillation, while left atrial appendage (LAA)...
ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
November 05, 2018 08:30 ET
|
ARCA biopharma, Inc.
Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc....
ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
September 18, 2018 08:30 ET
|
ARCA biopharma, Inc.
Gencaro potentially the first genetically-targeted treatment for heart failure patients at risk for atrial fibrillationPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that...